1

2

3

4

5

6
Dixon Julie, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, Lee Wendy, Sibley Robert, Bear Brian, Chandler Brent, Miranda Karl, Chen Gang, Chen Zhi, Brittelli David, Clark Roger B: 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors. Bayer Pharmaceuticals Corporation, Dixon Julie, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, Lee Wendy, Sibley Robert, Bear Brian, Chandler Brent, Miranda Karl, Chen Gang, Chen Zhi, Brittelli David, Clark Roger B, GREENMAN Jeffrey M, April 3, 2003: WO/2003/026666 (3 worldwide citation)

The invention provides novel substituted 2,4-diaminopyrimidine compounds (I), in which L is a linker selected from: -O-(CH¿2?)¿1-4?- ; s(O)¿0-2?-(CH¿2?)¿1-4?- ; -N(R?1¿)-(CH¿2?)¿1-4?-(CH¿2?)¿1-4?-O-(CH¿2?)¿1-4?- ; -N(R?1¿)-C(O)-(CH¿2?)¿1-4?- ; (I) and (I) G represents: Alternatively, L may represent ...


7
Dixon Julie, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, Lee Wendy, Sibley Robert, Bear Brian: 2−phenylamino−4− (5−pyrazolylamino) −pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors. Bayer Corporation, Dixon Julie, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, Lee Wendy, Sibley Robert, Bear Brian, GREENMAN Jeffrey M, April 3, 2003: WO/2003/026664 (2 worldwide citation)

The invention provides novel substituted 2,4−diaminopyrimidine compounds (I). In formula (I), the variables are as follows. Y1 represents H or C 1−4 alkyl. Y2 represents CF3, C1−6 alkyl; C3−6 cycloalkyl; or phenyl optionally substituted with halogen, C1−4 alkyl, or C1−4 alkoxy. The subscri ...


8
Vallari Anadruzela S, Hackett John R Jr, Hickman Robert K, Varitek Vincent A Jr, Necklaws Elizabeth C, Golden Alan M, Brennan Catherine A, Devare Sushil G: Rapid assay for simultaneous detection and differentiation of antibodies to hiv. Abbott Lab, May 31, 2000: EP1004023-A2 (1 worldwide citation)

A method of performing a rapid assay for the simultaneous detection and differentiation of the analytes HIV-1 group M, HIV-1 group O and HIV-2 utilizing a sequence specific polypeptide of each analyte as capture reagents. An analytical device also is provided for performing the method which includes ...


9
Dixon Julie, Scott William J, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia: 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors. Bayer Pharmaceuticals Corporation, Dixon Julie, Scott William J, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, GREENMAN Jeffrey M, April 3, 2003: WO/2003/026665 (1 worldwide citation)

This application discloses and claims 5-substituted-2,4-diaminopyrimidines, (I) in which R?1¿ represents C¿1-6? alkyl, C¿3-6? cycloalkyl, adamantyl, phenyl, or a 5-membered heteroaromatic containing a single heteroatom selected from N, O, and S. R?2¿ represents H, F, Cl, or C¿1-4? alkyl. R?3¿ repres ...


10
HACKETT JOHN R JR, YAMAGUCHI JULIE, GOLDEN ALAN M, BRENNAN CATHERINE A, HICKMAN ROBERT K: [fr] Constructions dantigène utiles dans la détection et la différentiation danticorps du VIH, [de] Antigen-Konstrukte, für den Nachweis und die Unterscheidung von Antikörpern gegen HIV, [en] Antigen constructs useful in the detection and differentiation of antibodies to HIV. ABBOTT LAB, April 6, 2011: EP2305818-A2

[en] Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 group M env polypeptide and (b) further antigen constructs containing additional Gr ...